Miguel Esperança-Martins

Prof. Dr. Miguel Esperança-Martins

Centro Hospitalar Universitário Lisboa Norte
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MEMiguel Esperança-Martins
Miguel Esperança-Martins
DRDiogo Roque
Diogo Roque
TBTiago Barroso
Tiago Barroso
ABAndré Abrunhosa Branquinho
André Abrunhosa Branquinho
DBDiogo Belo
Diogo Belo
LCLuis Costa
Luis Costa
Metastatic spine disease (MSD) and metastatic spinal cord compression (MSCC) are major causes of permanent neurological damage and long-term disability for cancer patients. The development of MSD is pathophysiologically framed by a cooperative interaction between general mechanisms of bone growth and specific mechanisms of spinal metastases (SM) expansion. SM most commonly affects the thoracic spine, even though multiple segments may be affected concomitantly. The great majority of SM are extradural, while intradural-extramedullary and intramedullary metastases are less frequently seen. The management of patients with SM is particularly complex and challenging, with multiple factors—such as the spinal stability status, primary tumor radio and chemosensitivity, cancer biological burden, patient performance status and comorbidities, and patient’s oncological prognosis—influencing the clinical decision-making process. Different frameworks were developed in order to systematize and support this process. A multidisciplinary, personalized approach, enriched by the expertise of each involved specialty, is crucial. We reviewed the most recent evidence and proposed an updated algorithmic approach to patients with MSD according to the clinical scenario of each patient. A flowchart-based approach offers an evidence-based management of MSD, providing a valuable clinical decision tool in a context of high uncertainty and quick-acting need.

15 August 2023 in Cells
Verified
Journal Article
Open access
PDF file
LGLisa Gonçalves
Lisa Gonçalves
DGDuarte Gonçalves
Duarte Gonçalves
TETeresa Esteban-Casanelles
Teresa Esteban-Casanelles
TBTiago Barroso
Tiago Barroso
IPInês Soares de Pinho
Inês Soares de Pinho
LCLuis Costa
Luis Costa
Although the impact of circadian timing on immunotherapy has yet to be integrated into clinical practice, chronoimmunotherapy is an emerging and promising field as circadian oscillations are observed in immune cell numbers as well as the expression of immunotherapy targets, e.g., programmed cell death protein-1 and its ligand programmed death ligand 1. Concurrent retrospective studies suggest that morning infusions may lead to higher effectiveness of immune checkpoint inhibitors in melanoma, non-small cell lung cancer, and kidney cancer. This paper discusses the results of a retrospective study (2016–2022) exploring the impact of infusion timing on the outcomes of all 73 patients with stage IV melanoma receiving immunotherapy at a particular medical center. While the median overall survival (OS) was 24.2 months (95% confidence interval [CI] 9.04–39.8), for a median follow-up of 15.3 months, our results show that having more than 75% of infusions in the afternoon results in shorter median OS (14.9 vs. 38.1 months; hazard ratio 0.45 [CI 0.23–0.86]; p < 0.01) with more expressive impacts on particular subgroups: women, older patients, and patients with a lower tumor burden at the outset of immunotherapy. Our findings highlight the potential benefits of follow-up validation in prospective and translational randomized studies.

Verified
Journal Article
Open access
PDF file
IFIsabel Fernandes
Isabel Fernandes
CMCecilia Melo-Alvim
Cecilia Melo-Alvim
RLRaquel Lopes-Brás
Raquel Lopes-Brás
MEMiguel Esperança-Martins
Miguel Esperança-Martins
LCLuis Costa
Luis Costa
Osteosarcoma (OS) is a rare condition with very poor prognosis in a metastatic setting. Basic research has enabled a better understanding of OS pathogenesis and the discovery of new potential therapeutic targets. Phase I and II clinical trials are already ongoing, with some promising results for these patients. This article reviews OS pathogenesis and new potential therapeutic targets.

2 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MEMiguel Esperança-Martins
Miguel Esperança-Martins
CMCecilia Melo-Alvim
Cecilia Melo-Alvim
SDSara Dâmaso
Sara Dâmaso
RLRaquel Lopes-Brás
Raquel Lopes-Brás
TPTânia Peniche
Tânia Peniche
LCLuis Costa
Luis Costa
Breast sarcomas (BSs), phyllodes tumors (PTs), and desmoid tumors (DTs) are rare entities that arise from connective tissue. BSs can be classified as either primary or secondary, whether they develop de novo or after radiation exposure or lymphedema. PIK3CA seems to play an important common role in different BS. Malignant PTs show similar behavior to BSs, while DTs are locally aggressive but rarely metastasize. BSs usually present as unilateral, painless, rapidly growing masses with rare nodal involvement. The diagnosis should be based on magnetic resonance imaging and a core needle biopsy. Staging should comprise a chest computed tomography (CT) scan (except for benign PT and DT), while abdominal and pelvic CT scans and bone scans should be added in certain subtypes. The mainstay of treatment for localized BS is surgery, with margin goals that vary according to subtype. Radiotherapy and chemotherapy can be used as neoadjuvant or adjuvant approaches, but their use in these settings is not standard. Advanced BS should be treated with systemic therapy, consistent with recommendations for advanced soft tissue sarcomas of other topographies. Given the rarity and heterogeneity of these entities, multidisciplinary and multi-institutional collaboration and treatment at reference centers are critical.

Verified
Journal Article
Open access
PDF file
RLRaquel Lopes-Brás
Raquel Lopes-Brás
DLDolores Lopez-Presa
Dolores Lopez-Presa
MEMiguel Esperança-Martins
Miguel Esperança-Martins
CMCecília Melo-Alvim
Cecília Melo-Alvim
LGLina Gallego
Lina Gallego
IFIsabel Fernandes
Isabel Fernandes
Sarcomas are rare malignant mesenchymal neoplasms, and the knowledge of tumor biology and genomics is scarce. Chemotherapy is the standard of care in advanced disease, with poor outcomes. Identifying actionable genomic alterations may offer effective salvage therapeutic options when previous lines have failed. Here, we report a retrospective cohort study of sarcoma patients followed at our center and submitted to comprehensive genomic profiling between January 2020 and June 2021. Thirty patients were included, most (96.7%) with reportable genomic alterations. The most common alterations were linked to cell cycle regulation (TP53, CDKN2A/B, and RB1 deletions and CDK4, MDM2, and MYC amplifications). Most patients (96.7%) had microsatellite stability and low tumor mutational burden (≤10 muts/megabase (Mb); median 2 Muts/Mb). Two-thirds of patients had actionable mutations for targeted treatments, including five cases with alterations amenable to targeted therapies with clinical benefit within the patient’s tumor type, ten cases with targetable alterations with clinical benefit in other tumor types, and five cases with alterations amenable to targeting with drugs under investigation in a clinical trial setting. A significant proportion of cases in this study had actionable genomic alterations with available targeted drugs. Next-generation sequencing is a feasible option for identifying molecular drivers that can provide therapeutic options for individual patients. Molecular Tumor Boards should be implemented in the clinical practice to discuss genomic findings and inform clinically relevant targeted therapies.

8 June 2021 in Cells
Verified
Journal Article
Open access
PDF file
MEMiguel Esperança-Martins
Miguel Esperança-Martins
IFIsabel Fernandes
Isabel Fernandes
JBJoaquim Soares do Brito
Joaquim Soares do Brito
DMDaniela Macedo
Daniela Macedo
HVHugo Vasques
Hugo Vasques
Sérgio DiasSérgio Dias
Sérgio Dias
The vast array of metabolic adaptations that cancer cells are capable of assuming, not only support their biosynthetic activity, but also fulfill their bioenergetic demands and keep their intracellular reduction–oxidation (redox) balance. Spotlight has recently been placed on the energy metabolism reprogramming strategies employed by cancer cells to proliferate. Knowledge regarding soft tissue and bone sarcomas metabolome is relatively sparse. Further characterization of sarcoma metabolic landscape may pave the way for diagnostic refinement and new therapeutic target identification, with benefit to sarcoma patients. This review covers the state-of-the-art knowledge on cancer metabolomics and explores in detail the most recent evidence on soft tissue and bone sarcoma metabolomics.